Sharon L. Crowell-Davis, Thomas F. Murray (University of Georgia), Leticia Mattos de Souza Dantas

Veterinary Psychopharmacology

• Gebundenes Buch

Produktbeschreibung

Offers an updated second edition of the comprehensive reference on the use of drugs for veterinary mental health care and behavior modification

This fully revised Second Edition of Veterinary Psychopharmacology offers an authoritative reference to the drugs prescribed to treat psychiatric, psychological, and behavioral disorders in pets. Designed to be an accessible resource, the text is divided into sections on psychopharmacologic principles and clinical psychopharmacology. Comprehensive in scope, the book contains detailed information on pharmacologic intervention for pet mental health and behavior issues, offers thorough explanations of options, and explores why a particular drug should be prescribed and why it works.

Updated to include the recent advances in psychopharmacology for pets, the Second Edition includes new chapters that cover the principles of psychopharmacology, miscellaneous serotonergic agents, anticonvulsants and mood stabilizers, sympatholyticagents, and NMDA antagonists. In addition, the text explains the drug options, including all the information necessary to correct dysfunctions in the brain's chemistry through pharmacologic treatment. This important resource:
_ Presents an updated and comprehensive resource for pharmacologic treatments for pet, equine, and zoo animal psychiatric disorders and behavior problems
_ Contains in-depth information on drugs that promote neurochemical changes that will alter the mood, emotional state, reactivity, and behavior of the patient, including prescribing options and mechanisms of action
_ Includes new chapters on the principles of psychopharmacology, miscellaneous serotonergic agents, mood stabilizers, sympatholytic agents, and NMDA antagonists

Written for veterinarians, veterinary behaviorists, and veterinary students, the updated second edition of Veterinary Psychopharmacology is a complete source for current knowledge on pharmacologic behavior modification.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Wiley & Sons / Wiley-Blackwell
• Artikelnr. des Verlages: 1A119226220
• 2. Aufl.
• Seitenzahl: 336
• Erscheinungstermin: 15. März 2019
• Englisch
• Abmessung: 260mm x 183mm x 22mm
• Gewicht: 859g
• ISBN-13: 9781119226222
• ISBN-10: 1119226228
• Artikelnr.: 53447515

Autorenporträt

The Authors The Editors Sharon L. Crowell-Davis, DVM, PhD, DACVB, is a Professor of Behavioral Medicine in the Department of Veterinary Biosciences and Diagnostic Imaging, College of Veterinary Medicine, the University of Georgia in Athens, Georgia, USA. Thomas F. Murray, PhD, is a Professor of Pharmacology and Provost of Creighton University in Omaha, Nebraska, USA. Leticia Mattos de Souza Dantas, DVM, MS, PhD, DACVB is a Clinical Assistant Professor of Behavioral Medicine at the University of Georgia Veterinary Teaching Hospital and the Department of Veterinary Biosciences and Diagnostic Imaging at the College of Veterinary Medicine, University of Georgia in Athens, Georgia, USA. She is also the Director and Co-founder of ZooPsych, Inc., a consultancy in Clinical Behavioral Medicine & Therapy in Georgia, USA.

Inhaltsangabe

Contributors xxi

Preface xxiii

Acknowledgments xxv

Part I Principles of Veterinary Psychopharmacology 1

1 General Principles of Psychopharmacology 3
Thomas F. Murray

Drug Action 3

Dose Dependence of Drug Interaction with Receptors 4

Structural Features of the Central Nervous System (CNS) and Neurotransmission 5

Biogenic Amine Neurotransmitters and Affective Disorders 8

2 Amino Acid Neurotransmitters: Glutamate, GABA, and the Pharmacology of Benzodiazepines 11
Thomas F. Murray

Introduction 11

Glutamatergic Synapses 11

Pharmacology of Ketamine and Tiletamine 14

GABAergic Synapses 15

3 Biogenic Amine Neurotransmitters: Serotonin 21
Thomas F. Murray

Introduction 21

The Biogenic Amines 21

Serotonin 22

4 Biogenic Amine Transmitters: Acetylcholine, Norepinephrine, and Dopamine 29
Thomas F. Murray

Acetylcholine 29

Norepinephrine 32

Dopamine 37

5 Neuropeptides: Opioids and Oxytocin 43
Thomas F. Murray

Introduction 43

Endogenous Opioid Peptides 43

Oxytocin 47

Part II Practice of Veterinary Psychopharmacology 51

6 Introduction to Clinical Psychopharmacology for Veterinary Medicine 53
Sharon L. Crowell-Davis and Leticia Mattos de Souza Dantas

Introduction 53

Prescribing in the United States: The Animal Medicinal Drug Use Clarification Act (AMDUCA 1994) 54

Cost 55

Drug Selection 56

Medicating the Patient 57

Competition Animals 58

Taking the Behavioral History 58

The Behavioral Exam 63

Duration of Treatment 63

Limitations 64

7 Benzodiazepines 67
Leticia Mattos de Souza Dantas and Sharon L. Crowell-Davis

Action 67

Overview of Indications 67

Contraindications, Side Effects, and Adverse Events 69

Overdose 69

Clinical Guidelines 69

Specific Medications 71

I. Alprazolam 71

II. Chlordiazepoxide HC1 73

IV. Clorazepate Dipotassium 78

V. Diazepam 80

VI. Flurazepam Hydrochloride 86

VII. Lorazepam 87

VIII. Oxazepam 89

IX. Triazolam 91

8 Selective Serotonin Reuptake Inhibitors 103
Niwako Ogata, Leticia Mattos de Souza Dantas, and Sharon L. Crowell-Davis

Action 103

Overview of Indications 103

Contraindications, Side Effects, and Adverse Events 104

Adverse Drug Interactions 104

Overdose 105

Clinical Guidelines 105

Specific Medications 106

I. Citalopram Hydrobromide 106

II. Fluoxetine Hydrochloride 108

III. Fluvoxamine 115

IV. Paroxetine Hydrochloride 117

V. Sertraline Hydrochloride 119

VI. Escitalopram Oxalate 122

9 Miscellaneous Serotonergic Agents 129
Leticia Mattos de Souza Dantas and Sharon L. Crowell-Davis

Introduction 129

Azapirones 129

Action 129

Overview of Indications 129

Contraindications, Side Effects, and Adverse Events 129

Adverse Drug Interactions 129

Overdose 129

Clinical Guidelines 129

Specific Medications 130

I. Buspirone 130

I. Trazodone Hydrochloride 135

10 Anticonvulsants and Mood Stabilizers 147
Sharon L. Crowell-Davis, Mami Irimajiri, and Leticia Mattos de Souza Dantas

Action 147

Overview of Indications 148

Clinical Guidelines 148

Specific Medic